Catumaxomab is a trivalent antibody that crosslinks CD3+ T cells with epithelial cell adhesion molecule (EpCAM) expressing tumours in the presence of FcR-bearing myeloid antigen presenting cells, which primes cellular and humoral responses against tumour antigens [18]. Here, EPCAM is linked to neoplasm.